Does the media prefer ADMA or PBYI?

In the previous week, Puma Biotechnology had 7 more articles in the media than ADMA Biologics. MarketBeat recorded 13 mentions for Puma Biotechnology and 6 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.31 beat Puma Biotechnology's score of 0.43 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Puma Biotechnology 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PBYI or CTMX?

In the previous week, Puma Biotechnology had 7 more articles in the media than CytomX Therapeutics. MarketBeat recorded 13 mentions for Puma Biotechnology and 6 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.72 beat Puma Biotechnology's score of 0.43 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CytomX Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PBYI or TRDA?

In the previous week, Puma Biotechnology had 3 more articles in the media than Entrada Therapeutics. MarketBeat recorded 13 mentions for Puma Biotechnology and 10 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.67 beat Puma Biotechnology's score of 0.43 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Entrada Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IMCR or PBYI?

In the previous week, Puma Biotechnology had 9 more articles in the media than Immunocore. MarketBeat recorded 13 mentions for Puma Biotechnology and 4 mentions for Immunocore. Immunocore's average media sentiment score of 0.73 beat Puma Biotechnology's score of 0.43 indicating that Immunocore is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Puma Biotechnology 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Puma Biotechnology (PBYI) Competitors

$9.41 -0.28 (-2.89%)

As of 04:00 PM Eastern

Compare

PBYI vs. ADMA, CTMX, TRDA, DMRA, and IMCR

Should you buy Puma Biotechnology stock or one of its competitors? Puma Biotechnology's main competitors and comparable companies include ADMA Biologics (ADMA), CytomX Therapeutics (CTMX), Entrada Therapeutics (TRDA), Damora Therapeutics, Inc. Common Stock (DMRA), and Immunocore (IMCR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Puma Biotechnology compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Puma Biotechnology (NASDAQ:PBYI) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

ADMA Biologics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

ADMA Biologics has a net margin of 32.98% compared to Puma Biotechnology's net margin of 11.50%. ADMA Biologics' return on equity of 40.17% beat Puma Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Puma Biotechnology	11.50%	20.76%	13.22%

ADMA Biologics has higher revenue and earnings than Puma Biotechnology. ADMA Biologics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.21	$146.93M	$0.70	13.69
Puma Biotechnology	$228.40M	2.13	$31.11M	$0.52	18.10

In the previous week, Puma Biotechnology had 7 more articles in the media than ADMA Biologics. MarketBeat recorded 13 mentions for Puma Biotechnology and 6 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.31 beat Puma Biotechnology's score of 0.43 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Puma Biotechnology	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADMA Biologics currently has a consensus target price of $18.67, suggesting a potential upside of 94.85%. Puma Biotechnology has a consensus target price of $6.00, suggesting a potential downside of 36.24%. Given ADMA Biologics' stronger consensus rating and higher probable upside, research analysts clearly believe ADMA Biologics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

ADMA Biologics beats Puma Biotechnology on 12 of the 16 factors compared between the two stocks.

How does Puma Biotechnology compare to CytomX Therapeutics?

Puma Biotechnology (NASDAQ:PBYI) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Puma Biotechnology has higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.13	$31.11M	$0.52	18.10
CytomX Therapeutics	$76.20M	10.52	-$17.37M	-$0.50	N/A

Puma Biotechnology has a net margin of 11.50% compared to CytomX Therapeutics' net margin of -435.21%. Puma Biotechnology's return on equity of 20.76% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Puma Biotechnology currently has a consensus price target of $6.00, indicating a potential downside of 36.24%. CytomX Therapeutics has a consensus price target of $11.90, indicating a potential upside of 223.37%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CytomX Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Puma Biotechnology had 7 more articles in the media than CytomX Therapeutics. MarketBeat recorded 13 mentions for Puma Biotechnology and 6 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.72 beat Puma Biotechnology's score of 0.43 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CytomX Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Puma Biotechnology has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market.

Summary

Puma Biotechnology beats CytomX Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Puma Biotechnology compare to Entrada Therapeutics?

Puma Biotechnology (NASDAQ:PBYI) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

In the previous week, Puma Biotechnology had 3 more articles in the media than Entrada Therapeutics. MarketBeat recorded 13 mentions for Puma Biotechnology and 10 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.67 beat Puma Biotechnology's score of 0.43 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entrada Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Puma Biotechnology has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

Puma Biotechnology has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.13	$31.11M	$0.52	18.10
Entrada Therapeutics	$4.69M	59.58	-$143.75M	-$3.96	N/A

Puma Biotechnology has a net margin of 11.50% compared to Entrada Therapeutics' net margin of -3,537.73%. Puma Biotechnology's return on equity of 20.76% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%

Puma Biotechnology presently has a consensus target price of $6.00, indicating a potential downside of 36.24%. Entrada Therapeutics has a consensus target price of $17.75, indicating a potential upside of 147.56%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Puma Biotechnology beats Entrada Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Puma Biotechnology compare to Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Damora Therapeutics, Inc. Common Stock currently has a consensus target price of $44.00, indicating a potential upside of 57.14%. Puma Biotechnology has a consensus target price of $6.00, indicating a potential downside of 36.24%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, equities research analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

Puma Biotechnology has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A
Puma Biotechnology	$228.40M	2.13	$31.11M	$0.52	18.10

Puma Biotechnology has a net margin of 11.50% compared to Damora Therapeutics, Inc. Common Stock's net margin of 0.00%. Puma Biotechnology's return on equity of 20.76% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%
Puma Biotechnology	11.50%	20.76%	13.22%

In the previous week, Puma Biotechnology had 8 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 13 mentions for Puma Biotechnology and 5 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.72 beat Puma Biotechnology's score of 0.43 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Puma Biotechnology	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Comparatively, 22.2% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Puma Biotechnology beats Damora Therapeutics, Inc. Common Stock on 10 of the 16 factors compared between the two stocks.

How does Puma Biotechnology compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

In the previous week, Puma Biotechnology had 9 more articles in the media than Immunocore. MarketBeat recorded 13 mentions for Puma Biotechnology and 4 mentions for Immunocore. Immunocore's average media sentiment score of 0.73 beat Puma Biotechnology's score of 0.43 indicating that Immunocore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Puma Biotechnology	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Puma Biotechnology has a net margin of 11.50% compared to Immunocore's net margin of -4.20%. Puma Biotechnology's return on equity of 20.76% beat Immunocore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
Puma Biotechnology	11.50%	20.76%	13.22%

Immunocore currently has a consensus target price of $56.38, indicating a potential upside of 50.05%. Puma Biotechnology has a consensus target price of $6.00, indicating a potential downside of 36.24%. Given Immunocore's stronger consensus rating and higher possible upside, equities research analysts plainly believe Immunocore is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.69
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Puma Biotechnology has lower revenue, but higher earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	4.84	-$35.51M	-$0.37	N/A
Puma Biotechnology	$228.40M	2.13	$31.11M	$0.52	18.10

Immunocore has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

84.5% of Immunocore shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 10.1% of Immunocore shares are owned by insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Puma Biotechnology beats Immunocore on 9 of the 17 factors compared between the two stocks.

Get Puma Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBYI vs. The Competition

Export

Metric	Puma Biotechnology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$485.74M	$4.02B	$7.25B	$12.89B
Dividend Yield	N/A	3.61%	2.53%	8.57%
P/E Ratio	18.10	12.72	273.59	25.45
Price / Sales	2.13	1,361.39	675.80	123.67
Price / Cash	11.21	105.29	76.98	52.10
Price / Book	3.51	16.29	12.89	6.14
Net Income	$31.11M	-$22.72M	$3.47B	$349.01M
7 Day Performance	1.84%	-1.38%	-0.33%	-1.47%
1 Month Performance	22.37%	11.06%	6.51%	2.47%
1 Year Performance	83.43%	53.71%	25.19%	15.84%

Puma Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBYI Puma Biotechnology	1.1234 of 5 stars	$9.41 -2.9%	$6.00 -36.2%	+89.6%	$485.74M	$228.40M	18.10	200	Trending News Analyst Revision
ADMA ADMA Biologics	3.6575 of 5 stars	$9.71 +1.6%	$18.67 +92.3%	-44.7%	$2.18B	$510.17M	13.88	530
CTMX CytomX Therapeutics	2.5647 of 5 stars	$3.39 +2.9%	$11.90 +251.6%	+78.8%	$737.59M	$76.20M	N/A	170	Positive News
TRDA Entrada Therapeutics	2.4777 of 5 stars	$7.46 +1.7%	$17.75 +138.1%	+35.7%	$290.67M	$4.69M	N/A	110	Analyst Upgrade Insider Trade
DMRA Damora Therapeutics, Inc. Common Stock	2.6114 of 5 stars	$31.09 +2.6%	$44.00 +41.5%	+839.3%	$1.92B	N/A	N/A	40	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBYI) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Puma Biotechnology (PBYI) Competitors

PBYI vs. ADMA, CTMX, TRDA, DMRA, and IMCR

How does Puma Biotechnology compare to ADMA Biologics?

Summary

How does Puma Biotechnology compare to CytomX Therapeutics?

Summary

How does Puma Biotechnology compare to Entrada Therapeutics?

Summary

How does Puma Biotechnology compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Puma Biotechnology compare to Immunocore?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI vs. The Competition

Puma Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Puma Biotechnology (PBYI) Competitors

PBYI vs. ADMA, CTMX, TRDA, DMRA, and IMCR

How does Puma Biotechnology compare to ADMA Biologics?

Do insiders and institutionals hold more shares of ADMA or PBYI?

Which has more volatility and risk, ADMA or PBYI?

Is ADMA or PBYI more profitable?

Which has stronger valuation & earnings, ADMA or PBYI?

Does the media prefer ADMA or PBYI?

Do analysts prefer ADMA or PBYI?

Summary

How does Puma Biotechnology compare to CytomX Therapeutics?

Which has higher valuation and earnings, PBYI or CTMX?

Is PBYI or CTMX more profitable?

Do insiders & institutionals have more ownership in PBYI or CTMX?

Do analysts recommend PBYI or CTMX?

Does the media favor PBYI or CTMX?

Which has more volatility and risk, PBYI or CTMX?

Summary

How does Puma Biotechnology compare to Entrada Therapeutics?

Does the media favor PBYI or TRDA?

Do institutionals and insiders have more ownership in PBYI or TRDA?

Which has more risk & volatility, PBYI or TRDA?

Which has stronger earnings & valuation, PBYI or TRDA?

Is PBYI or TRDA more profitable?

Do analysts recommend PBYI or TRDA?

Summary

How does Puma Biotechnology compare to Damora Therapeutics, Inc. Common Stock?

Do analysts prefer DMRA or PBYI?

Which has more volatility and risk, DMRA or PBYI?

Which has higher earnings & valuation, DMRA or PBYI?

Is DMRA or PBYI more profitable?

Does the media refer more to DMRA or PBYI?

Do insiders and institutionals believe in DMRA or PBYI?

Summary

How does Puma Biotechnology compare to Immunocore?

Does the media refer more to IMCR or PBYI?

Is IMCR or PBYI more profitable?

Do analysts recommend IMCR or PBYI?

Which has preferable valuation & earnings, IMCR or PBYI?

Which has more risk & volatility, IMCR or PBYI?

Do insiders & institutionals have more ownership in IMCR or PBYI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI vs. The Competition

Puma Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools